Vijaya Diagnostic Centre Share Price Target 2025, 2026, 2030, 2040, 2050

Vijaya Diagnostic Centre is a well-known healthcare centre in India. It provides many medical tests and advanced scans like MRI, CT, PET-CT, and other special tests. It has more than 200 centres in states like Telangana, Andhra Pradesh, West Bengal, Karnataka, Maharashtra, and NCR, using a system of big labs and smaller collection centres to reach more people. The centre has skilled doctors and modern machines. It also offers convenient services like home sample collection, online booking, and digital reports.

What is Vijaya Diagnostic Centre Ltd NSE: VIJAYA?

Vijaya Diagnostic Centre was established in 1978 in Hyderabad, Telangana, and is run by Dr A. Balasubramanian. It is a well-known healthcare centre in India. The centre does many medical tests like blood tests, urine tests, X-rays, ultrasound, CT scans, MRI scans, and health check-ups. It has many branches in big cities and uses modern machines with skilled staff. Vijaya Diagnostic gives correct results on time and cares for patients. They also collect samples from home, making tests easy and safe. The centre follows clean and safe practices and works to make healthcare simple and affordable for everyone.

Vijaya Diagnostic Centre Share Price Target

Vijaya Diagnostic Centre Share Price Target 2025

It offers high-quality blood tests and scans and has gradually expanded to many services and locations. It has long experience and focuses on accurate testing; it is trusted by patients, doctors, and hospitals. The centre focuses on patient care, modern technology, and building a network of centres that provide fast, reliable, and safe medical tests across India. In 2025, its share price target would be ₹1280, as per stock market analysts.

According to stock market analysts, its share price would be between ₹740 to ₹1280 in 2025.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	740	1280

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	898	1275
February	740	1192
March	895	1159
April	813	1180
May	885	1054
June	924	1014
July	971	1164
August	981	1099
September	995	1120
October	959	1130
November	946	1064
December	885	1280

Vijaya Diagnostic Centre Share Price Target 2026

It provides a wide range of medical tests. Pathology tests include blood tests, urine tests, microbiology, molecular testing, and tests for specific diseases. Radiology services include MRI scans, CT scans, PET-CT scans, ultrasound, X-rays, and nuclear medicine. The centre also offers heart tests, 3T MRI, and other special imaging services. Most routine and advanced tests are available in one place. In 2026, its share price target would be ₹1000, as per stock market analysts.

According to stock market analysts, its share price would be between ₹1000 to ₹1791 in 2026.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2026	1000	1791

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	1000	1390
February	1268	1435
March	1290	1465
April	1332	1489
May	1358	1500
June	1387	1541
July	1411	1578
August	1435	1611
September	1458	1657
October	1484	1678
November	1525	1732
December	1578	1791

Share Price Target 2027

It has a large network of more than 200 centres across states such as Telangana, Andhra Pradesh, Karnataka, West Bengal, Maharashtra, and NCR. This helps patients in cities and towns access tests easily. The centre follows a “hub and spoke” system: big labs (hubs) handle complex tests, while smaller collection centres (spokes) collect samples locally. This system allows faster testing and reporting. People in smaller towns can get high-quality tests without travelling far, making healthcare more accessible and convenient. In 2027, its share price target would be ₹2300, as per stock market analysts.

According to stock market analysts, its share price would be between ₹1700 to ₹2300 in 2027.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2027	1700	2300

Share Price Target 2028

The centre uses modern machines and technology. It has advanced MRI scanners, CT scanners, PET-CT machines, 3T MRI, and other equipment for accurate imaging. The labs use modern instruments for precise blood, urine, and molecular tests. Technology allows faster results and better management of patients. Digital reporting and online booking make it easy for patients. In 2028, its share price target would be ₹2763, as per stock market analysts.

According to stock market analysts, its share price would be between ₹2232 to ₹2763 in 2028.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2028	2232	2763

Share Price Target 2029

It provides home sample collection for patients who cannot visit the centre. Its trained staff safely collect blood, urine, or other samples at home. This is helpful for elderly patients, children, and those with mobility issues. The samples are sent securely to labs, and results are shared digitally. Home collection saves time, reduces infection risk, and makes tests available to more people, showing the centre’s focus on patient-friendly healthcare. In 2029, its share price target would be ₹3201, as per stock market analysts.

According to stock market analysts, its share price would be between ₹2711 to ₹3201 in 2029.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2029	2711	3201

Vijaya Diagnostic Centre share price Target 2030

The centre emphasises digital services. Patients can book tests online and get digital reports on the website or mobile app. This saves time and makes it easy for doctors and patients to view results. Digital reports are secure, easy to share, and stored for future use. Online services also include appointment booking, test tracking, and health package selection. Using technology helps the centre work efficiently, reduces waiting time, and gives patients a smooth, modern, and safe experience. In 2030, its share price target would be ₹3631, as per stock market analysts.

According to stock market analysts, its share price would be between ₹3144 to ₹3631 in 2030.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2030	3144	3631

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	3144	3289
February	3178	3312
March	3200	3358
April	3225	3375
May	3258	3415
June	3287	3475
July	3321	3490
August	3335	3525
September	3357	3564
October	3390	3588
November	3451	3610
December	3480	3631

Share Price Target 2040

It offers health checkup packages for different ages and health needs. Packages may include general tests, heart checkups, diabetes monitoring, liver and kidney tests, and cancer screenings. These checkups help find health issues early, so patients can get treatment quickly. Doctors explain the results and suggest follow-ups if needed. Preventive health checkups encourage awareness, early diagnosis, and long-term well-being. Packages make it easier for people to monitor their health and stay healthy. In 2040, its share price target would be ₹5942, as per stock market analysts.

According to stock market analysts, its share price would be between ₹5457 to ₹5942 in 2040.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2040	5457	5942

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	5457	5580
February	5487	5612
March	5508	5678
April	5521	5712
May	5535	5755
June	5548	5781
July	5574	5800
August	5590	5823
September	5612	5845
October	5645	5867
November	5678	5890
December	5690	5942

Share Price Target 2050

The centre follows high-quality standards to ensure correct results. Its labs are NABL-accredited and follow ISO rules, meeting international standards. Regular checks, audits, and staff training keep tests accurate and reliable. These standards build trust with patients, doctors, and healthcare partners. Accreditation ensures all tests are safe, precise, and reliable, which is important for correct medical decisions. Keeping high standards is key to the centre’s goal of providing world-class diagnostic services in all its locations. In 2050, its share price target would be ₹8116, as per stock market analysts.

According to stock market analysts, its share price would be between ₹7679 to ₹8116 in 2050.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2050	7679	8116

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	7679	7800
February	7690	7842
March	7710	7874
April	7725	7900
May	7743	7935
June	7752	7954
July	7768	7978
August	7784	8012
September	7912	8045
October	7920	8058
November	7933	8077
December	7950	8116

Should I buy Vijaya Diagnostic Centre stock?

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	740	1280
2026	1000	1791
2027	1700	2300
2028	2232	2763
2029	2711	3201
2030	3144	3631
2040	5457	5942
2050	7679	8116

It is a well-known healthcare and diagnostic company in India, mainly in Southern India, with more than 200 centres across different states. Its stock has grown steadily over time because of its strong network, many types of medical tests, and convenient services like home sample collection and online reports. Most experts suggest it as a “buy” and see a chance for the price to rise, but the stock is currently a bit expensive, which may limit short-term gains. People who want to invest for the long term and can handle some ups and downs may buy it.

Vijaya Diagnostic Centre earnings results

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales +	339	377	462	459	548	681	732
Expenses +	206	211	259	277	327	408	440
Operating Profit	133	166	204	182	221	273	291
OPM %	39%	44%	44%	40%	40%	40%	40%
Other Income +	15	12	13	14	19	17	23
Interest	15	15	16	21	24	27	29
Depreciation	49	50	53	62	57	71	80
Profit before tax	83	112	147	114	159	193	204
Tax %	25%	24%	25%	25%	25%	26%
Net Profit +	63	85	111	85	120	144	152
EPS in Rs	138.00	18.64	10.76	8.29	11.61	13.94	14.78
Dividend Payout %	0%	0%	9%	12%	9%	14%	—

Key Metrics

TTM PE Ratio	PB Ratio	Dividend Yield	Sector PE	Sector PB	Sector Div Yld
66.99	12.71	0.20%	36.54	5.77	0.59%

Peers & Comparison

Stock	PE Ratio	PB Ratio	Dividend Yield
Vijaya Diagnostic Centre Ltd	71.01	12.71	0.20%
Max Healthcare Institute Ltd	98.14	11.26	0.14%
Apollo Hospitals Enterprise Ltd	70.47	9.18	0.18%
Fortis Healthcare Ltd	84.82	7.16	0.11%

Is Vijaya Diagnostic Centre stock good to buy? (bull case & bear case)

Bull Case:

• In Q2 FY2025‑26, revenue grew 10.2% to ₹201–₹207 crore, and net profit rose 2.7–2.8%.
• In Q1 FY2025‑26, revenue grew 20.38% and net profit 22.30%, showing consistent performance.
• In FY2024‑25, sales grew 24.4% and net profit 20.4%, showing strong yearly growth.
• Rising demand for diagnostics in India supports long-term growth.
• Services like home collection, online booking, and digital reports attract more patients.
• More patients and higher test volumes support revenue growth.
• Strong EBITDA margins of ~40% show good profitability.

Bear Case:

• In Q2 FY2025‑26, net profit grew only 2.7% and margins fell slightly due to rising costs.
• Expenses rose about 13.8% in Q4, reducing profit.
• Profit growth can fluctuate each quarter.
• Competition from other diagnostic companies could limit growth.

Conclusion

It is a well-known healthcare company in India with over 200 centres. It provides advanced tests like MRI, CT, PET-CT, and also offers home sample collection and digital reports. The company has been growing steadily, and demand for its services is increasing. However, rising costs, profit changes, and competition are possible risks. People who want to invest for the long term and can handle some ups and downs may consider buying, while short-term investors should be careful.

FAQs